source
- MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighterDespite mixed results for its experimental schizophrenia treatment last month, MapLight Therapeutics is going all-in on the asset—at the expense of its preclinical programs.Fierce Biotech · 5h ago↗ source
- Taiho and Cullinan report positive Phase 3 results for zipalertinib in EGFR exon 20 insertion lung cancerTaiho Oncology and Cullinan Therapeutics announced that their experimental drug zipalertinib achieved positive results in a Phase 3 trial for first‑line treatment of lung cancer patients whose tumo…